ILMN vs. MEDP: Illumina vs. Medpace Stock Comparison
How do Illumina (ILMN) and Medpace (MEDP) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Illumina (ILMN) and Medpace (MEDP) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | ILMN | MEDP |
|---|---|---|
| Name | Illumina Inc. | Medpace Holdings, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 32.23 billion USD | 18.27 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 28, 2000 | August 11, 2016 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ILMN | MEDP |
|---|---|---|
| Total Return (1Y) | 79.70% | 13.29% |
| Total Return (3Y, Annualized) | 28.16% | 35.26% |
| Total Return (5Y, Annualized) | -10.65% | 24.49% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ILMN | MEDP |
|---|---|---|
| Volatility (1Y, Annualized) | 48.47% | 44.16% |
| Beta (5Y) | 1.46 | 1.10 |
| Max Drawdown (5Y) | -82.95% | -42.87% |
| Avg. Volume (3M) | 2.77M | 258.39K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ILMN | MEDP |
|---|---|---|
| Sharpe Ratio (1Y) | 1.56 | 0.20 |
| Sortino Ratio (1Y) | 2.25 | 0.26 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Illumina (ILMN) at 32.39% also sits in the top quartile.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.39%
- Max
- 109.18%
- ILMN
- 32.39%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.88%
- MEDP
- 117.88%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Illumina (ILMN) at 19.72% and Medpace (MEDP) at 18.24% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.72%
- ILMN
- 19.72%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.24%
- MEDP
- 18.24%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Illumina (ILMN) at 20.02% and Medpace (MEDP) at 23.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.02%
- Max
- 83.12%
- ILMN
- 20.02%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.12%
- Max
- 83.12%
- MEDP
- 23.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ILMN | MEDP |
|---|---|---|
| ROE (TTM) | 32.39% | 117.88% |
| ROA (TTM) | 8.32% | 18.71% |
| Net Margin (TTM) | 19.72% | 18.24% |
| Operating Margin (TTM) | 20.02% | 23.12% |
| Gross Margin (TTM) | 67.68% | 72.24% |
Growth
Revenue Growth
Medpace (MEDP) at 19.97% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.
Growth Metrics
| Metric | ILMN | MEDP |
|---|---|---|
| Revenue Growth (YoY) | -0.66% | 19.97% |
| Revenue Growth (3Y CAGR) | -1.78% | 20.12% |
| EPS Growth (YoY) | -- | 20.98% |
| EPS Growth (3Y CAGR) | -- | 28.04% |
Financial Strength
Current Ratio (MRQ)
Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ILMN
- 2.63
- Q1
- 2.47
- Min
- 0.10
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MEDP
- 0.83
- Min
- 0.10
Debt / Equity (MRQ)
Medpace (MEDP) at 0.29 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.74
- Max
- 1.42
- ILMN
- 0.74
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.29
- Max
- 1.42
- Q3
- 0.65
- MEDP
- 0.29
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ILMN | MEDP |
|---|---|---|
| Current Ratio (MRQ) | 2.63 | 0.83 |
| Debt / Equity (MRQ) | 0.74 | 0.29 |
| Net Debt / EBITDA | 0.85 | -0.84 |
Dividends
Dividend Yield (TTM)
Neither Illumina (ILMN) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Illumina (ILMN) nor Medpace (MEDP) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ILMN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ILMN | MEDP |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Illumina (ILMN) at 36.68 and Medpace (MEDP) at 36.26 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.68
- Max
- 85.34
- Q3
- 43.46
- ILMN
- 36.68
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.26
- Max
- 85.34
- Q3
- 43.46
- MEDP
- 36.26
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Illumina (ILMN) at 7.10 and Medpace (MEDP) at 6.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.10
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ILMN
- 7.10
- Q1
- 3.01
- Min
- 0.01
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- MEDP
- 6.44
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Illumina (ILMN) at 10.30 sits in the upper P/B ratio quartile, and Medpace (MEDP) at 31.23 prices even higher, above its industry range.
ILMN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.30
- Max
- 13.53
- ILMN
- 10.30
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.23
- MEDP
- 31.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ILMN | MEDP |
|---|---|---|
| P/E Ratio (TTM) | 36.68 | 36.26 |
| P/S Ratio (TTM) | 7.10 | 6.44 |
| P/B Ratio (MRQ) | 10.30 | 31.23 |
| Free Cash Flow Yield (TTM) | 2.67% | 2.72% |